National Vision Holdings, Inc. — Form 10-Q Summary
Period clarification: The filing covers the 13 weeks ended April 2, 2022 (fiscal first quarter 2022), compared with the 13 weeks ended April 3, 2021. This differs from the request metadata indicating 2021 Q1.
Business context
National Vision is a U.S. value optical retailer, operating 1,292 locations across its owned and host brands and its Walmart management-services arrangement. It reported two segments: Owned & Host and Legacy. The company opened 17 stores during the quarter and had 62 more stores than a year earlier.
Financial performance
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Net revenue | $527.7 million | $534.2 million | Down 1.2% |
| Income from operations | $37.3 million | $61.4 million | Down 39.2% |
| Operating margin | 7.1% | 11.5% | Down 4.4 percentage points |
| Net income | $30.1 million | $43.4 million | Down 30.6% |
| Diluted EPS | $0.34 | $0.48 | Down $0.14 |
| Adjusted EBITDA | $68.6 million | $89.4 million | Down 23.2% |
| Adjusted EBITDA margin | 13.0% | 16.7% | Down 3.7 percentage points |
Revenue decline reflected weaker comparable-store sales, partly offset by new stores and deferred revenue recognition. Comparable-store sales fell 4.9% (adjusted comparable-store sales fell 6.8%), following 18.2% growth in the prior-year quarter. Product sales declined 2.2%; services and plans sales increased 3.7%. Owned & Host revenue fell 3.2% and Legacy revenue fell 3.3%.
Costs applicable to revenue rose to 44.7% of sales from 42.1%, primarily due to higher optometrist-related costs, lower eyeglass margins and reduced eyeglass mix. SG&A increased to 43.3% of revenue from 41.9%, reflecting higher advertising, store payroll and occupancy expenses. Adjusted diluted EPS was $0.33 versus $0.48.
Cash flow, debt and liquidity
- Operating cash flow was $47.1 million, down from $97.7 million; the company attributed the reduction to lower earnings and less favorable working-capital movements.
- Capital expenditures were $28.1 million, versus $16.4 million, largely reflecting investment in doctor and remote-medicine equipment. Financing activities used $9.9 million, including share repurchases.
- Cash and cash equivalents were $314.6 million at April 2, 2022; cash, cash equivalents and restricted cash totaled $316.0 million. The company reported $293.6 million available under its revolving credit facility, including $6.4 million of outstanding letters of credit.
- Debt included $402.5 million principal of 2.50% convertible notes due 2025 and a $150.0 million term loan due 2024. The reported carrying amount of long-term debt, before finance leases, was $544.2 million. The company was in compliance with debt covenants.
- The company repurchased approximately 0.2 million shares for $7.1 million during the quarter; $123.0 million remained under its repurchase authorization.
Outlook, commentary and risks
- Management expected to open at least 80 stores in fiscal 2022. It stated that cash on hand, operating cash flow and revolver availability should cover working-capital needs, anticipated capital expenditures and debt payments for the next 12 months and the foreseeable future.
- Management linked weaker sales to Omicron-related traffic impacts, constrained eye-exam capacity and macroeconomic pressures. It cited optometrist recruitment and retention, remote-medicine initiatives and marketing optimization as responses.
- Inflation, wage and input-cost increases, supply-chain disruption, labor shortages, changing consumer demand and geopolitical uncertainty—including the conflict in Ukraine—could pressure sales, costs and margins. The pandemic’s duration and effects remained uncertain.
- Pricing changes occurred around the filing period: Eyeglass World’s opening offer increased effective March 14, 2022, and America’s Best’s signature offer increased effective May 9, 2022.
- Interest income, net, was $4.1 million, compared with interest expense of $6.3 million a year earlier, primarily because of gains on the interest-rate collar as rates rose. The collar had a $6.6 million fair-value asset at quarter-end. Variable-rate debt exposure and benchmark-rate changes remain risks.
- The filing describes ordinary-course legal claims but provides no clear quantified estimate of potential loss. Management reported effective disclosure controls and no material change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the reporting-period discrepancy: the filing is for Q1 2022, not Q1 2021.
- Track whether comparable-store sales, exam capacity and optometrist availability recover, and whether announced store openings are achieved.
- Assess whether price increases offset higher labor, occupancy, product and service costs without further weakening demand.
- Monitor operating cash flow, capital spending, share repurchases, revolver availability and debt service as the business expands.
- Review the effects of interest-rate movements and the convertible notes’ potential dilution; the filing states conversion price conditions were not met at quarter-end.